Dr. Sharon Schendel serves as the Program Manager for the Coronavirus Immunotherpeautics Consortium (CoVIC) where she develops antibody therapies for low- and middle-income countries dealing with COVID-19. In addition to developing novel therapies, Dr. Shendel is passionate about helping scientists develop writing and oral skills and even established the US Editorial Office for The Biochemical Journal when she worked at Sanford Burnham Prebys. She holds a Bachelors degree in Chemistry and a PhD in Biophysics from Purdue University.
